A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Sponsor: Hoffmann-La Roche • ClinicalTrials.gov ID: NCT05091424
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
This study will assess the safety, tolerability, pharmaokinetics, and preliminary efficacy of mosunetuzumab (Lunsumio) monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed by the treating physician to continue their BTKi throughout the screening period and for the first three cycles of mosunetuzumab. An additional arm (open to non-US participants only) has been added to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of mosunetuzumab in combination with venetoclax, a B-cell lymphoma 2 (BCL2) inhibitor, compared to standard-of-care rituximab plus venetoclax.
Interventions
-
Mosunetuzumab
(Drug)
Participants will receive subcutaneous (SC) mosunetuzumab.
-
Tocilizumab
(Drug)
Participants will receive intravenous (IV) tocilizumab as needed for cytokine release syndrome (CRS) events.
-
Venetoclax
(Drug)
Participants will receive daily oral venetoclax.
-
Rituximab
(Drug)
Participants will receive IV rituximab as per protocol.
Eligibility criteria
Conditions
Locations
- Mayo Clinic Rochester — Rochester, Minnesota, United States
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States
- The James Cancer Hospital and Solove Research Institute — Columbus, Ohio, United States
- Uni of Texas - Md Anderson Cancer Center — Houston, Texas, United States
- Huntsman Cancer Institute at The University of Utah — Salt Lake City, Utah, United States
- Princess Alexandra Hospital Woolloongabba — Woolloongabba, Queensland, Australia
- Peter MacCallum Cancer Center — East Melbourne, Victoria, Australia
- Monash Medical Centre — Melbourne, Victoria, Australia
- Peking University People's Hospital — Beijing, China
- Southern Medical University Nanfang Hospital — Guangzhou, China
- The First Affiliated Hospital of Nanchang University — Nanchang, China
- Tianjin Institute of Hematology & Blood Diseases Hospital — Tianjin, China
- Chu de Clermont Ferrand — Clermont-Ferrand, France
- IUCT Oncopole — Toulouse, France
- Universitätsklinikum Augsburg — Augsburg, Germany
- Uniklinik Koln — Cologne, Germany
- Universitätsklinikum Ulm — Ulm, Germany
- A.O. Spedali Civili Di Brescia-P.O. Spedali Civili — Brescia, Lombardy, Italy
- Osp. San Raffaele — Milan, Lombardy, Italy
- Asst Grande Ospedale Metropolitano Niguarda — Milan, Lombardy, Italy
- Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia — Sant'Andrea Delle Fratte (PG), Umbria, Italy
- Uniwersyteckie Centrum Kliniczne — Gda?sk, Poland
- PRATIA MCM Kraków — Krakow, Poland
- Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu — Wroc?aw, Poland
- Seoul National University Hospital — Seoul, South Korea
- Seoul St Mary's Hospital — Seoul, South Korea
- Yeouido St. Mary's Hospital — Seoul, South Korea
- Hospital de la Santa Creu i Sant Pau — Barcelona, Spain
- Hospital Universitari Vall d'Hebron — Barcelona, Spain
- Christie Hospital NHS Trust — Manchester, United Kingdom
- Churchill Hospital — Oxford, United Kingdom
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record